Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;35(5):423-429.
doi: 10.1097/ICU.0000000000001066. Epub 2024 Jun 6.

Ocular manifestations of mpox

Minh Nguyen  1   2 , Thuy Doan  1   2 , Gerami D Seitzman  1   2
Affiliations
Review

Ocular manifestations of mpox

Minh Nguyen et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: To highlight the clinical features of mpox with an emphasis on ocular manifestations and to review treatment options for this re-emerging infectious disease.

Recent findings: Ocular involvement of mpox varies by clade. The most recent 2022 outbreak appears to be associated with fewer conjunctivitis cases compared to previous outbreaks. However, the ocular findings occurring during this newly emerging clade can be visually threatening and include cases of keratitis, rapidly progressing scleritis, and necrotizing periorbital rashes.

Summary: Ocular mpox is an important clinical feature of systemic mpox virus (MPXV) infection. Heightened clinical suspicion allows for a timely diagnosis and the initiation of antiviral treatment, when appropriate. Randomized clinical trials for mpox systemic and ocular treatment efficacy are lacking. Prior clinical experience with smallpox and in-vitro mpox data support the use of systemic antivirals such as tecovirimat, cidofovir, brincidofovir and topical use of trifluridine in ocular mpox management, though treatment-resistant infection can occur and portend a poor prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: No relevant conflicts of interest.

Dr. Seitzman is a consultant for Dompé pharmaceuticals, Kedrion biopharma, and Tarsus pharmaceuticals.

Similar articles

See all similar articles

Cited by

References

    1. Kaler J, Hussain A, Flores G et al. Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus 2022; 14:e26531. - PMC - PubMed
    1. Kieser Q, Noyce RS, Shenouda M et al. Cytoplasmic factories, virus assembly, and DNA replication kinetics collectively constrain the formation of poxvirus recombinants. PLoS One 2020; 15:e0228028. - PMC - PubMed
    1. Lansiaux E, Jain N, Laivacuma S, Reinis A. The virology of human monkeypox virus (hMPXV): A brief overview. Virus Res 2022; 322:198932. - PMC - PubMed
    1. Lefkowitz EJ, Wang C, Upton C. Poxviruses: past, present and future. Virus Res 2006; 117:105–118. - PubMed
    1. Wang L, Shang J, Weng S et al. Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022. J Med Virol 2023; 95:e28036. - PMC - PubMed

Substances